このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Topical Ruxolitinib Evaluation in Immune-related Vitiligo-like Depigmentation (TRuE-VLD)

2026年7月20日 更新者:Lara Maul-Duwendag、University of Zurich

Topical Ruxolitinib for the Treatment of Immune-related Vitiligo-like Depigmentation: A Prospective, Multicentre Study of a Topical JAK-inhibitor

White spot disease is a common side effect on the skin in the context of cancer treatments with immunotherapies. There is no standard therapy yet for white spot caused by cancer therapies. There is already research in humans on the treatment of white spot disease. Previous human studies with ruxolitinib cream have shown that approximately 30% of patients with white spot disease have achieved a 75% improvement (re-pigmentation) of their affected areas after 24 weeks and approximately 50% of patients have achieved a 75% improvement after 52 weeks. It is also know that a 50% improvement was observed in over 50% of patients after 24 weeks and a 90% improvement in over 15% of patients. However, these studies to date have not included patients with white spot disease caused by cancer therapy. Therefore, we do not know how well the cream works in this situation. In this study, the investigators are therefore examining whether the investigational substance ruxolitinib is effective and well tolerated in white spot disease caused by cancer therapy. The test substance has not yet been approved in Switzerland. Only once the efficacy of the investigational substance ruxolitinib has been scientifically investigated and proven can it be approved in Switzerland and used to treat white spot disease caused by cancer therapy.

調査の概要

状態

積極的、募集していない

条件

介入・治療

研究の種類

介入

入学 (推定)

34

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Zurich、スイス、8058
        • Universitätsspital Zürich

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

Adult patients eligible for this inclusion in this study have to fulfil all the following criteria:

  • Age 18 years
  • Written informed consent of the patient
  • Sufficient fluency in German language skills to complete all questionnaires of the study without external assistance
  • Treatment-related, immune-related vitiligo-like depigmentation of at least 5% body surface area of one region (face or one upper or lower extremity or front or back side of the trunk)
  • Female participants must use effective contraceptives, either: An ovulation-inhibiting method (e.g., pill, injectable, implant, patch, or vaginal ring) or an intrauterine device (IUD). Contraception should extend one week post-study. If pregnancy occurs during or within one week after the study, participants should notify the overseeing physician immediately.
  • During participation in the study and up to one week afterwards, male participants may only have sexual intercourse with condoms. Female partners of male participants must use a highly effective contraceptive method during the partner's participation in the study and for up to 1 week afterwards

Exclusion Criteria:

Patients fulfilling any of the following criteria are not eligible for the inclusion in this study:

  • Acute psychiatric illness (except mild to moderate depression)
  • Contraindications to ruxolitinib, e.g. known hypersensitivity or allergy
  • Use of topical glucocorticosteroids, topical calcineurin inhibitors, UV light therapy, therapeutic biologics, other JAK inhibitors or potent immunosuppressants such as azathioprine or cyclosporine are not allowed during the study period (no wash out period required).
  • Women who are pregnant or breast feeding
  • Intention to become pregnant during the course of the study
  • Known or suspected non-compliance, drug or alcohol abuse.
  • Patients with an active, serious infection, including localized infections.
  • Inability to follow the procedures of the study due to language problems, psychological disorders, dementia of the participant.
  • Participation in another trial with topical or oral ruxolitinib within the 30 days preceding and during the present study.
  • Simultaneously participation in clinical trials with intervention with a drug other than ruxolitinib (except registry studies)
  • Previous enrolment into the current study.
  • Enrolment of the investigator, his/her family members, employees and other dependent persons.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Topical ruxolitinib
This study will be performed as one-arm with no comparator.
Ruxolitinib cream 1.5% will be applied topically twice daily over 52 weeks in patients with immune-related vitiligo-like depigmentation.
他の名前:
  • Topical Ruxolitinib (OPZELURA)

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Proportion of patients achieving a Facial vitiligo scoring index of 75% (F-VASI75) at week 24
時間枠:week 24
The F-VASI is a measure for assessing the success of treatment. The F-VASI assesses the percentage of repigmentation on the face. Achieving an F-VASI of 75% means that a 75% improvement in facial repigmentation has been achieved. This is determined by visually assessing the percentage of skin area that has returned to its normal color as a result of the treatment. The F-VASI is made up of the degree of depigmentation in percent and the size of the affected skin surface in percent. Percentage of depigmentation (0% = no depigmentation present, 100% = completely depigmented skin) is multiplied by the size of the affected skin area on the face in percent.
week 24

二次結果の測定

結果測定
メジャーの説明
時間枠
Proportion of patients achieving a F-VASI of 25%, 50% and 90% (F-VASI25/50/90)
時間枠:week 24 and 52
The F-VASI assesses the percentage of repigmentation on the face. Achieving an F-VASI of 50% means that a 50% improvement in facial repigmentation has been achieved. The same applies to an F-VASI of 25% or 90%; this corresponds to 25% respectively 90% repigmentation. The F-VASI is made up of the degree of depigmentation in percent and the size of the affected skin surface in percent. Percentage of depigmentation (0% = no depigmentation present, 100% = completely depigmented skin) is multiplied by the size of the affected skin area on the face in percent.
week 24 and 52
Proportion of patients achieving a F-VASI 75 only at week 52
時間枠:week 52
The F-VASI assesses the percentage of repigmentation on the face. Achieving an F-VASI of 75% means that a 75% improvement in facial repigmentation has been achieved. The F-VASI is made up of the degree of depigmentation in percent and the size of the affected skin surface in percent. Percentage of depigmentation (0% = no depigmentation present, 100% = completely depigmented skin) is multiplied by the size of the affected skin area on the face in percent.
week 52
Proportion of patients achieving a Total Vitiligo Area Scoring Index of 25%, 50%, 75% and 90% (T-VASI25/50/75/90)
時間枠:week 24 and 52
T-VASI is a measure used to evaluate the success of vitiligo treatment over the entire body. A T-VASI of for instance 75% means that a 75% improvement in repigmentation of the entire skin of the body has been achieved. The T-VASI is calculated by estimating and weighting the area of depigmented skin and the degree of repigmentation. Percentage of depigmentation (0% = no depigmentation present, 100% = completely depigmented skin) is multiplied by the affected body surface area in percent. The unit of "Proportion of patients achieving a Total Vitiligo Area Scoring Index of 25%, 50%, 75% and 90% (T-VASI25/50/75/90)" is a percentage. It is looked at what percentage of participants have achieved an improvement in their T-VASI score. It is looked at how many participants have achieved a 25% improvement, how many a 50% improvement, how many a 75% improvement and how many a 90% improvement in their T-VASI score.
week 24 and 52
Proportion of patients achieving 4 points ("a lot less noticeable") or 5 points ("no longer noticeable") in the Vitiligo Noticeability Scale (VNS)
時間枠:week 24 and 52
The VNS is an assessment tool developed to measure the visibility, conspicuousness and appearance of vitiligo spots. The score has a scale from one to five. One means more noticeable, five means no noticeability/visibility.
week 24 and 52
Percentage change from baseline in the Facial Body Surface Area (F-BSA) and Total Body Surface Area (T-BSA)
時間枠:week 24 and 52
Calculation of the affected body surface area as a percentage. Once the affected surface on the face and once the affected surface on the entire integument.
week 24 and 52
Percentage change from baseline in the Facial Physician's Global Vitiligo Assessment (F-PhGVA) and Total Physician's Global Vitiligo Assessment (T-PhGVA)
時間枠:week 24 and 52

The F-PhGVA is an assessment tool used by physicians to evaluate the severity of facial vitiligo. It is based on a global assessment by the treating physician and takes into account various aspects of the disease, including the area and extent of depigmentation as well as the aesthetic impairment. The assessment is made on a numerical scale, categorizing different degrees of severity of facial vitiligo. The scale ranges from 0 to 4, with 0 corresponding to skin with no signs of vitiligo/complete repigmentation and 4 corresponding to very severe vitiligo.

The T-PhGVA is a global assessment of the disease across the entire body. It has the same numerical scale as the F-PhGVA, ranging from 0 to 4, with 0 corresponding to skin with no signs of vitiligo/complete repigmentation and 4 corresponding to very severe vitiligo.

Both scores are useful tools for evaluating the success of treatment for vitiligo on the face and the entire body and for documenting the progress of patients.

week 24 and 52
Change in disease stability
時間枠:week 24 and 52
The change of disease stability is defined as an exclusion of progressive vitiligo over a 1-year period with no increase in size of existing vitiligo foci, no new vitiligo foci, no Koebner phenomenon
week 24 and 52
Proportion of patient reported outcome: Dermatology Life Quality Index (DLQI)
時間枠:baseline, week 24 and 52
Dermatology Life Quality Index (DLQI): 10 questions, summing the score of each question resulting in a minimum of 0 and a maximum of 30 points
baseline, week 24 and 52
Proportion of patient reported outcome: Treatment Satisfaction Questionnaire for Medication (TSQM)
時間枠:baseline, week 24 and 52
Treatment Satisfaction Questionnaire for Medication (TSQM): questionnaire used to measure patient satisfaction with medication. The score ranges from 0 to 100 points
baseline, week 24 and 52
Proportion of patient reported outcome: Vitiligo Noticeability Scale (VNS)
時間枠:baseline, week 24 and 52
Vitiligo Noticeability Scale (VNS): score with a scale from one to five. One means more noticeable, five means no noticeability/visibility.
baseline, week 24 and 52
Proportion of patient reported outcome: Color-matching questions
時間枠:baseline, week 24 and 52
Color-matching questions: The patient assesses how well the color of the skin affected by VLD matches the surrounding, unaffected skin after treatment. Five answer options with a grading between "excellent" and "very poor" are possible.
baseline, week 24 and 52
Proportion of patient reported outcome: Facial Patient Global Impression of Change-Vitiligo (F-PaGIC-V)
時間枠:baseline, week 24 and 52
Facial Patient Global Impression of Change-Vitiligo (F-PaGIC-V): Patients assess the change in VLD on their face since starting treatment with the drug. Seven answer options are possible with a grading of "very much improved" and "very much worse"
baseline, week 24 and 52
Proportion of patient reported outcome: Total Body Patient Global Impression of Change-Vitiligo (T-PaGIC-V)
時間枠:baseline, week 24 and 52
Total Body Patient Global Impression of Change-Vitiligo (T-PaGIC-V): Patients assess the change of VLD on their total body since starting treatment with the drug. Seven answer options are possible with a grading of "very much improved" and "very much worse"
baseline, week 24 and 52
Proportion of patient reported outcome: Five Well-Being Index (WHO-5)
時間枠:baseline, week 24 and 52
Five Well-Being Index (WHO-5): a short self-reported measure of current mental wellbeing. It consists of five statements, which respondents rate according to a scale between 0 to 5
baseline, week 24 and 52
Proportion of patient reported outcome: Hospital Anxiety and Depression Scale (HADS)
時間枠:baseline, week 24 and 52
Hospital Anxiety and Depression Scale (HADS): is used to measure anxiety and depression in patients with physical illnesses. The severity of anxious and depressive symptoms during the past week is recorded by means of self-assessment on two subscales with seven items each. The total sum score can be used as a measure of general psychological impairment.
baseline, week 24 and 52
Proportion of patient reported outcome: Vitiligo Quality of Life Index (VitiQoL)
時間枠:baseline, week 24 and 52
Vitiligo Quality of Life Index (VitiQoL): specially developed instrument to measure the quality of life of people with vitiligo. It captures the psychosocial and emotional impact of the disease on the daily lives of those affected. As vitiligo can have not only physical but also significant psychological and social effects, the VitiQoL is a valuable tool to assess these comprehensively. Contains 16 questions.
baseline, week 24 and 52
Proportion of patient reported outcome: load thermometer
時間枠:baseline, week 24 and 52
The patient must indicate on a scale from zero to ten how much the VLD is bothering them. Grading from "not at all burdensome" to "extremely burdensome".
baseline, week 24 and 52

その他の成果指標

結果測定
メジャーの説明
時間枠
Assessment of skin shave biopsies
時間枠:Baseline and week 52
Differences in the cutaneous immune microenvironment in skin shave biopsies will be investigated using multi-omics technics. Histology, immune-histology, multiplex and single-cell RNA sequencing analyses will be performed.
Baseline and week 52

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年7月25日

一次修了 (実際)

2026年7月7日

研究の完了 (推定)

2026年8月31日

試験登録日

最初に提出

2024年5月31日

QC基準を満たした最初の提出物

2026年7月20日

最初の投稿 (実際)

2026年7月24日

学習記録の更新

投稿された最後の更新 (実際)

2026年7月24日

QC基準を満たした最後の更新が送信されました

2026年7月20日

最終確認日

2026年7月1日

詳しくは

本研究に関する用語

キーワード

その他の研究ID番号

  • 2023-01552

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。